open access

Vol 49, No 1 (2011)
Original paper
Published online: 2011-04-19
Submitted: 2011-12-19
Get Citation

Assessment of the pathway of apoptosis involving PAR-4, DAXX and ZIPK proteins in CLL patients and its relationship with the principal prognostic factors

Agnieszka Bojarska-Junak, Małgorzata Sieklucka, Iwona Hus, Ewa Wąsik-Szczepanek, Maria Luiza Kusz, Agata Surdacka, Sylwia Chocholska, Anna Dmoszyńska, Jacek Roliński
DOI: 10.5603/FHC.2011.0014
·
Folia Histochem Cytobiol 2011;49(1):98-103.

open access

Vol 49, No 1 (2011)
ORIGINAL PAPERS
Published online: 2011-04-19
Submitted: 2011-12-19

Abstract

Par-4 (prostate apoptosis response-4) protein was originally found upregulated in prostate tumor cells undergoing apoptosis. Then it was further identified as a proapoptotic protein upregulated both in normal and leukemic lymphocytes. The aim of our study was to assess PAR-4 protein expression in the B cells of CLL patients and to examine its relationship with the expression of other proteins involved in the apoptosis process, such as DAXX, ZIPK and BCL-2. We found a positive relationship between PAR-4 and BCL-2 protein expression. Additionally, there was a positive correlation between PAR-4 and both DAXX and ZIPK protein expression. The results of our research were also analyzed in association with the principal CLL prognostic factors. There was a positive correlation between the expression of PAR-4 protein and the lactate dehydrogenase (LDH) serum concentration (p < 0.005). The expression of PAR-4 protein in B cells correlated positively with the percentage of CD38+ cells (p < 0.05), as well as with CD38+/ZAP-70+ cells (p < 0.05). Moreover, we found a close relationship between LPL protein expression or LPL/ADAM29 MFI ratio and PAR-4 protein expression. Our results confirm the significance of apoptosis deregulation in CLL, and suggest a possible relationship between PAR-4 expression and the clinical course of the disease. This however requires further investigation. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 1, pp. 98–103)

Abstract

Par-4 (prostate apoptosis response-4) protein was originally found upregulated in prostate tumor cells undergoing apoptosis. Then it was further identified as a proapoptotic protein upregulated both in normal and leukemic lymphocytes. The aim of our study was to assess PAR-4 protein expression in the B cells of CLL patients and to examine its relationship with the expression of other proteins involved in the apoptosis process, such as DAXX, ZIPK and BCL-2. We found a positive relationship between PAR-4 and BCL-2 protein expression. Additionally, there was a positive correlation between PAR-4 and both DAXX and ZIPK protein expression. The results of our research were also analyzed in association with the principal CLL prognostic factors. There was a positive correlation between the expression of PAR-4 protein and the lactate dehydrogenase (LDH) serum concentration (p < 0.005). The expression of PAR-4 protein in B cells correlated positively with the percentage of CD38+ cells (p < 0.05), as well as with CD38+/ZAP-70+ cells (p < 0.05). Moreover, we found a close relationship between LPL protein expression or LPL/ADAM29 MFI ratio and PAR-4 protein expression. Our results confirm the significance of apoptosis deregulation in CLL, and suggest a possible relationship between PAR-4 expression and the clinical course of the disease. This however requires further investigation. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 1, pp. 98–103)
Get Citation

Keywords

PAR-4; DAXX; ZIPK; BCL-2; CD38; apoptosis; chronic lymphocytic leukemia

About this article
Title

Assessment of the pathway of apoptosis involving PAR-4, DAXX and ZIPK proteins in CLL patients and its relationship with the principal prognostic factors

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 49, No 1 (2011)

Article type

Original paper

Pages

98-103

Published online

2011-04-19

DOI

10.5603/FHC.2011.0014

Bibliographic record

Folia Histochem Cytobiol 2011;49(1):98-103.

Keywords

PAR-4
DAXX
ZIPK
BCL-2
CD38
apoptosis
chronic lymphocytic leukemia

Authors

Agnieszka Bojarska-Junak
Małgorzata Sieklucka
Iwona Hus
Ewa Wąsik-Szczepanek
Maria Luiza Kusz
Agata Surdacka
Sylwia Chocholska
Anna Dmoszyńska
Jacek Roliński

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl